<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882789</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-16-1-01</org_study_id>
    <nct_id>NCT02882789</nct_id>
  </id_info>
  <brief_title>IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Single Blind, Single Dose, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous Dosage Form of LCB01-0371 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary - To investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous dosage
      form of LCB01-0371 comparing to oral dosage in Healthy Male Volunteers Secondary

      â€¢ To investigate the absolute bio availability of LCB01-0371 after a single intravenous dose
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess Peak Plasma Concentration(Cmax) of LCB01-0371</measure>
    <time_frame>through study completion per patient, an average of 8 days (+ - 1 D)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LCB01-0371 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 IV 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCB01-0371 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 IV 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 IV 800 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371</intervention_name>
    <description>Cohort1 &amp; 3: Placebo-controlled, Single ascending dose administration</description>
    <arm_group_label>LCB01-0371 200mg</arm_group_label>
    <arm_group_label>LCB01-0371 400mg</arm_group_label>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <other_name>LCB01-0371 or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 400mg</intervention_name>
    <description>Cohort 2: Crossover designed administration</description>
    <arm_group_label>LCB01-0371 400mg</arm_group_label>
    <other_name>LCB01-0371 400mg 2 tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Male between 19 and 39 years of age at the time of screening

          2. Subjects with body mass index (BMI) between 19 and 27 at the time of screening

          3. Agree to continue to use a medically reliable dual contraception and not to donate
             sperm until 28 days of study completion

          4. Capable of giving written informed consent, willing to participate in this clinical
             trial, and willing to comply with all study requirements

        Exclusion Criteria:

          1. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer)
             which is affect to absorption OR surgical history except appendectomy, herniotomy

          2. History of allergy, cardiovascular, peripheral vascular, skin, mucous membrane, eyes,
             otorhinolaryngologic, respiratory, musculoskeletal, infectious disease,
             gastroenterologic, liver, billiary, endocrinologic, kidney, genitourinary,
             neuropsychiatric, hemato-oncologic problem(s) or fracture etc.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bae KS</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

